Perspective Therapeutics, Inc. (“Perspective” or the “Company”)
(NYSE AMERICAN: CATX), a radiopharmaceutical company that is
pioneering advanced treatment applications for cancers throughout
the body, today announced the closing of its previously announced
underwritten public offering of (i) 156,399,542 shares of its
common stock at the public offering price of $0.37 per share,
including the exercise in full by the underwriters of their option
to purchase up to an additional 24,324,324 shares of common stock
and (ii) to certain investors in lieu of common stock, pre-funded
warrants to purchase 30,086,944 shares of its common stock at a
price of $0.369 per pre-funded warrant. The purchase price per
share of each pre-funded warrant represents the per share public
offering price for the common stock, minus the $0.001 per share
exercise price of such pre-funded warrant. All of the shares of
common stock and pre-funded warrants sold in the public offering
were sold by Perspective. Gross proceeds to Perspective in the
public offering were approximately $69.0 million, before
underwriting discounts and commissions and estimated expenses of
the public offering.
Oppenheimer & Co. and B. Riley Securities
acted as joint book-running managers for the public offering.
Concurrent with the public offering, Perspective
closed its previously announced private placement of 56,342,355
shares of its common stock to Lantheus Alpha Therapy, LLC at a
price of $0.37 per share, for total gross proceeds of approximately
$20.8 million.
The aggregate gross proceeds from the public
offering and the concurrent private placement were approximately
$89.8 million, before underwriting discounts and commissions and
other offering expenses payable by Perspective.
Perspective intends to use the net proceeds from
the public offering and concurrent private placement for general
corporate purposes, which may include research and development
expenditures, preclinical study and clinical trial expenditures,
manufacturing expenditures, commercialization expenditures, working
capital, capital expenditures, acquisitions of new technologies,
products or businesses and investments.
The securities described above in the public
offering were offered by Perspective pursuant to a shelf
registration statement on Form S-3 (File No. 333-275638) initially
filed with the Securities and Exchange Commission (the “SEC”) on
November 17, 2023 and declared effective by the SEC on December 14,
2023.
The securities in the public offering were
offered by means of a prospectus supplement and accompanying
prospectus relating to the public offering that form a part of the
registration statement. A preliminary prospectus supplement
relating to the public offering was filed with the SEC on January
17, 2024. A final prospectus supplement relating to the public
offering was filed with the SEC and is available on the SEC’s
website at www.sec.gov. Copies of the final prospectus supplement
and accompanying prospectus relating to the public offering may be
obtained from Oppenheimer & Co. Inc., Attention: Syndicate
Prospectus Department, 85 Broad Street, 26th Floor, New York, NY
10004, or by telephone at (212) 667-8055, or by email at
EquityProspectus@opco.com, or from B. Riley Securities, Inc.,
Attention: Prospectus Department, 1300 17th Street North, Suite
1300, Arlington, Virginia 22209, Phone: (703) 312-9580, Email:
prospectuses@brileyfin.com.
The shares sold in the concurrent private
placement have not been registered under the Securities Act, or any
state or other applicable jurisdiction’s securities laws, and may
not be offered or sold in the United States absent registration or
an applicable exemption from the registration requirements of the
Securities Act and applicable state or other jurisdictions’
securities laws.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Perspective Therapeutics,
Inc.
Perspective Therapeutics, Inc., is a
radiopharmaceutical company that is pioneering advanced treatment
applications for cancers throughout the body. The Company has a
proprietary technology that utilizes the alpha emitting isotope
Lead-212 to deliver powerful radiation specifically to cancer cells
via specialized targeting peptides. The Company is also developing
complementary imaging diagnostics that incorporate the same
targeting peptides which provide the opportunity to personalize
treatment and optimize patient outcomes. This “theranostic”
approach enables the ability to see the specific tumor and then
treat it to potentially improve efficacy and minimize toxicity
associated with many other types of cancer treatments.
The Company’s melanoma (VMT01) and
neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a
imaging and therapy trials for the treatment of metastatic melanoma
and neuroendocrine tumors at several leading academic institutions
in the United States. The Company has also developed a proprietary
Lead-212 generator to secure key isotopes for clinical trial and
commercial operations.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE
SECURITIES LITIGATION ACT OF 1995: To the extent any
statements made in this press release deal with information that is
not historical, these are forward-looking statements under the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, statements regarding the
anticipated use of proceeds for the public offering and concurrent
private placement and other statements identified by words such as
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may
cause Perspective’s actual results to be materially different than
those expressed in or implied by Perspective’s forward-looking
statements. For Perspective, this includes stock price volatility
and uncertainties relating to the financial markets, the medical
community and the global economy, and the impact of instability in
general business and economic conditions, including changes in
inflation, interest rates and the labor market. More detailed
information on these and additional factors that could affect
Perspective’s actual results are described in Perspective’s filings
with the SEC, including its Transition Report on Form 10-KT
for the transition period ended December 31, 2022, as revised or
supplemented by its Quarterly Reports on Form 10-Q and other
documents filed with the SEC. All forward-looking statements in
this news release speak only as of the date of this news release.
Perspective undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Media and Investor Relations Contacts:
Russo Partners, LLC
Nic Johnson or Harrison Seidner, Ph.D.
E: Nic.johnson@russopartnersllc.com
E: Harrison.seidner@russopartnersllc.com
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
From Apr 2023 to Apr 2024